Defiance Daily Target 2X Long NVO ETF(NVOX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Defiance Daily Target 2X Long NVO ETF
NVOX.US
News
View More

Novo Nordisk's Wegovy Pill Records Nearly 20,000 Prescriptions in First Week

Novo Nordisk's new weight-loss pill, Wegovy, recorded 18,410 prescriptions in its first week in the U.S., according to IQVIA data. Analysts are monitoring its sales to assess Novo Nordisk's market share against Eli Lilly. The pill's oral format is expected to attract more consumers compared to previous injectable options. Guggenheim noted that Wegovy's prescription numbers are exceeding other GLP-1 launches. Novo Nordisk's stock has risen approximately 25% this year, driven by strong expectations for Wegovy.

Tip Ranks·
US
IXJ
-0.15%
US
FBT
-0.56%
US
LLY
-0.80%
Tip Ranks·
US
IXJ
-0.15%
US
FBT
-0.56%
US
LLY
-0.80%

Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch

Jan 23 (Reuters) - Novo Nordisk’s (NOVOb.CO) Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed.Investors are closely watching prescriptions data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lillyin a competitive weight-loss market.The pill hit 3,071 U.S. prescriptions in the first four days after its launch.“We note this is tracking ahead of other GLP-1 launches,” Guggenheim analysts said in a note.

Reuters·
US
LLY
-0.80%
US
NVO
+1.68%
US
NVOX
+3.26%
Reuters·
US
LLY
-0.80%
US
NVO
+1.68%
US
NVOX
+3.26%

08:01 ET CoreAge Rx Introduces Flat-Rate Pricing for GLP-1 Medications

CoreAge Rx, a telehealth pharmacy, has introduced a flat-rate pricing model for GLP-1 medications, including compounded semaglutide at $99/month and tirzepatide at $149/month when paid annually. This model aims to eliminate hidden fees and provide predictable costs for patients. All consultation fees, medications, and overnight shipping are included in a single annual payment, ensuring no surprises regardless of dosage changes. The telehealth service allows patients to manage their treatment online, with medications delivered within three to five business days. CoreAge Rx emphasizes accessibility and affordability in weight management solutions.

prnewswire·
US
LLYX
-1.64%
US
IXJ
-0.15%
US
SBIO
-1.81%
prnewswire·
US
LLYX
-1.64%
US
IXJ
-0.15%
US
SBIO
-1.81%

17:52 ET CoreAge Rx Expands GLP-1 Access to Support New Year Weight Loss Goals

CoreAge Rx, a telehealth pharmacy, has announced an expansion of its compounded GLP-1 weight management program to support New Year's weight loss goals. This initiative aims to increase access to medications like tirzepatide and semaglutide, addressing barriers such as cost and supply shortages. The expansion includes enhancements to their digital platform and patient education resources, ensuring consistent medication availability. CoreAge Rx's telehealth model allows patients to manage their treatment online, making effective weight management more accessible as many Americans set health resolutions for 2026.

prnewswire·
US
LLYX
-1.64%
US
PBE
-0.72%
US
NVOX
+3.26%
prnewswire·
US
LLYX
-1.64%
US
PBE
-0.72%
US
NVOX
+3.26%

Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record

Novo Nordisk's oral weight-loss pill, Wegovy, has achieved a record-breaking 500% surge in prescriptions, reaching 20,371 in its second week. This unprecedented growth outpaces competitors like Eli Lilly's Zepbound. The figure may be conservative, as it excludes direct-to-consumer sales and telehealth platforms. With distribution in over 70,000 locations, Novo is poised to dominate the market before Lilly's oral contender arrives in 2026. The GLP-1 market is entering a mass-market phase, potentially reshaping revenue trajectories for both companies.

benzinga_article·
US
XLV
-0.49%
US
LLY
-0.80%
US
PBE
-0.72%
benzinga_article·
US
XLV
-0.49%
US
LLY
-0.80%
US
PBE
-0.72%
Posts
View More
© 2026 Longbridge｜Disclaimer